Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase EARLY_PHASE1 5Phase 4 4Phase NA 3Phase 1/2 2Phase 1 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1CNS 1

Conditions

Neoplasm Metastasis 1Meningioma 1Memory Disorders 1Glioblastoma 1Cognitive Dysfunction 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Pioglitazone × Clear all
NCT02133625 2026-03-30

A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
14 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01151670 2018-08-01

Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

Wake Forest University Health Sciences

Phase 1 Completed
18 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Memory Disorders, Meningioma, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡